Rochester, New York 11/21/2009 5:00:00 AM
News / Business

Eminem Set to Release Relapse: Refill on December 21st Under Aftermath/Interscope Label

Interscope records has announced that multi-platinum hip hop giant, Eminem will release Relapse: Refill on December 21, 2009. The record will be release under the Aftermath/Interscope Record label. The re-release of Eminem's most recent album includes seven bonus tracks, including the single "Forever," featuring Drake, Kanye West, and Lil Wayne, "Taking My Ball," and five never before heard tracks.

 

Get Rich Penny Stocks is a leading financial publication that is pleased to alert investors of stocks on the move.

Sign Up for our Free Stock Newsletter

 

Eminem's, platinum selling album Relapse shot up the charts to hit Number 1 in May, 2009 on the Billboard Top 200 album charts. In the album's first week it had sold over 618,000 copies within the U.S. The album is also the top selling hip-hop album of '09.

 

Interscope Geffen A&M Records shines like a supernova in the musical universe. A division of recording industry titan Universal Music Group (UMG), Interscope Geffen oversees a diverse collection of record labels, including three of UMG's flagship imprints: Interscope, Geffen Records, and A&M Records. Interscope, best known for its rap and R&B artists, is responsible for some of UMG's best-selling albums, including works from top-sellers 50 cent and Eminem. Venerable A&M Records promotes a variety of artists such as Bryan Adams and Sheryl Crow. Geffen Records' focus is shifting from a mix of genres to commercial pop.

 

Sign up for the Free GetRichPennyStocks Newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.

 

About Us

 

GetRichPennyStocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that could be on the brink of a breakout. To feature a company on our web site please contact us at the email listed below.

 

Please click here to read the full disclaimer.